[Identification of functionally significant mutations in NAT2 gene using biological microchips]

Area of Science:

• Pharmacogenomics
• Molecular Diagnostics
• Biotechnology

Background:

• The NAT2 gene product is vital for biotransformation and detoxifying mutagenic arylamines.
• NAT2 activity influences the metabolism of numerous medications, impacting drug efficacy and toxicity.
• Genetic variations in NAT2 lead to diverse acetylation phenotypes, affecting individual responses to xenobiotics.

Purpose of the Study:

• To develop and validate a microchip for detecting functionally significant mutations in the NAT2 gene.
• To enable the identification of a wide range of NAT2 genotypes and their corresponding acetylation phenotypes.
• To establish a convenient screening method for NAT2 genetic polymorphisms.

Main Methods:

• Development of a microchip capable of detecting 16 key mutations in the NAT2 gene, covering 36 alleles.
• Genotyping analysis to determine over 660 possible NAT2 genotypes.
• Restriction analysis to ascertain cis-trans positions of specific mutations.

Main Results:

• The microchip successfully identified NAT2 genotypes in 37 out of 71 DNA samples.
• In 34 samples, more than two genotypes were identified, with 16 exhibiting a slow or intermediate acetylation phenotype (R/S or S/S).
• Specific mutations (282C/T, 341T/C, 481C/T, 590G/A, 803A/G) were consistently found in samples with the slow/intermediate acetylation phenotype.

Conclusions:

• The developed biochip serves as an efficient screening tool for identifying common NAT2 gene polymorphisms.
• This technology facilitates the classification of individuals into acetylation phenotype groups, relevant for personalized drug therapy.
• The microchip offers a practical approach for primary detection of the majority of polymorphic variations in the NAT2 gene.